| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00143-9546-01 | 00143-9546 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | May 1, 1996 | In Use | |
| 50268-0075-15 | 50268-0075 | ANASTROZOLE | ANASTROZOLE | 1.0 mg/1 | Hormonal Therapy | Aromatase Inhibitor | Oral | Oct 11, 2019 | In Use | ||
| 43598-0610-40 | 43598-0610 | Docetaxel | Docetaxel | 80.0 mg/4mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 22, 2017 | In Use | |
| 50242-0094-47 | 50242-0094 | ENTRECTINIB | Rozlytrek | 200.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | TRKA, TRKB, TRKC, ROS1, ALK | Oral | Aug 15, 2019 | In Use | |
| 10139-0321-01 | 10139-0321 | Melphalan Hydrochloride | Melphalan Hydrochloride | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Intravenous | Oct 27, 2009 | In Use | ||
| 60219-1714-02 | 60219-1714 | Lenalidomide | LENALIDOMIDE | 2.5 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 12, 2025 | In Use | |
| 42291-0870-01 | 42291-0870 | Tretinoin | Tretinoin | 10.0 mg/1 | Hormonal Therapy | Immunomodulator | Retinoic Acid Derivative | Oral | Feb 23, 2022 | In Use | |
| 58181-4321-04 | 58181-4321 | Temozolomide | Temozolomide | 100.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Apr 1, 2025 | In Use | |
| 63323-0132-15 | 63323-0132 | MITOXANTRONE HYDROCHLORIDE | Mitoxantrone | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracenedione | Intravenous | Apr 11, 2006 | In Use | |
| 68788-7565-01 | 68788-7565 | Ondansetron | Ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 27, 2019 | In Use | |
| 00003-4040-12 | 00003-4040 | Repotrectinib | Augtyro | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ROS1, TRKA, TRKB, TRKC | Oral | Dec 5, 2023 | In Use | |
| 63739-0588-10 | 63739-0588 | Prednisone | Prednisone | 20.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Jun 30, 2014 | Dec 31, 2025 | In Use |
| 68001-0416-36 | 68001-0416 | Leucovorin Calcium | Leucovorin Calcium | 100.0 mg/10mL | Ancillary Therapy | Chemoprotective | Antidote | Intramuscular, Intravenous | Sep 26, 2019 | In Use | |
| 42291-0280-50 | 42291-0280 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Feb 26, 2013 | May 31, 2020 | In Use |
| 67877-0288-01 | 67877-0288 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jan 5, 2017 | In Use | |
| 57902-0860-03 | 57902-0860 | Samarium SM 153 Lexidronam | Quadramet | 50.0 mCi/mL | Ancillary Therapy | Radiopharmaceutical | Samarium Sm 153 | Intravenous | May 19, 1997 | In Use | |
| 59572-0501-00 | 59572-0501 | Pomalidomide | Pomalyst | 1.0 mg/1 | Immunotherapy | Immunomodulator | Thalidomide Analog | Oral | Feb 18, 2013 | In Use | |
| 68071-3306-09 | 68071-3306 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jul 25, 2017 | In Use | |
| 00078-0715-02 | 00078-0715 | Alpelisib | PIQRAY | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | May 24, 2019 | In Use | ||
| 51817-0170-01 | 51817-0170 | Busulfan | Busulfan | 6.0 mg/mL | Chemotherapy | Alkylating Agent | Alkylsulfonate | Intravenous | May 19, 2017 | In Use | |
| 54569-0333-00 | 54569-0333 | Prednisone | Prednisone | 50.0 mg/1 | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Oral | Mar 14, 2003 | In Use | |
| 65162-0794-09 | 65162-0794 | Imatinib | Imatinib Mesylate | 100.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Feb 8, 2019 | In Use | |
| 50419-0395-72 | 50419-0395 | Darolutamide | Nubeqa | 300.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | Non-Steroidal | Oral | Mar 3, 2021 | In Use | |
| 63187-0670-15 | 63187-0670 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Dec 1, 2018 | In Use | |
| 64679-0726-01 | 64679-0726 | ondansetron hydrochloride | ONDANSETRON HYDROCHLORIDE | 2.0 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intramuscular, Intravenous | Dec 27, 2006 | In Use |
Found 12611 results — Export these results
Home